Clinical Collaboration

A Structured Investigation into Functional Recovery in Type 1 Diabetes

SweetFreedom is building a staged, publication-grade research pathway designed to test whether measurable functional recovery is biologically achievable in established Type 1 Diabetes, including beyond the honeymoon window.

This initiative rests on one belief: that real progress will come from the meeting of two worlds that usually operate separately – the scientific and clinical rigor of conventional medicine, and the multi-factorial, systems-oriented perspective of functional and integrative medicine. We need both.

So we are seeking clinical collaborators from both worlds – united by one commitment: disciplined, mechanism-driven, test-based investigation. The approach draws on emerging signals across immunology, metabolism, microbiome science, and beta-cell biology.

The Scientific Framing

The dominant model of Type 1 Diabetes focuses on autoimmune-mediated beta-cell destruction. Yet converging research suggests a more complex landscape:

  • Beta cells under inflammatory stress actively signal immune recruitment
  • Gut microbiome shifts frequently precede seroconversion
  • Persistent low-grade viral signatures may sustain islet stress
  • Alpha-beta signaling imbalance affects islet stability
  • Regeneration pathways appear biologically inducible under certain conditions

These signals remain largely investigated in isolation. SweetFreedom’s objective is to test whether sequencing systemic stress reduction and biological stabilization can create conditions permissive to functional recovery.

The Research Pathway

The investigation is staged. Each stage is designed to generate publication-grade data and to inform the next, under physician supervision and independent oversight.

Stage One: Case Series

A physician-supervised case series of 5-10 families, with 12-month aggregated biomarker tracking. This stage is designed and ready to launch; funding to begin it is the immediate priority. One family is already implementing the protocol under medical supervision.

  • Written collaboration agreements with treating physicians
  • Informed consent and aggregated biomarker tracking for each family
  • Purpose: generate structured pre-trial signal and refine the measurement plan

Stage Two: Phase 2a Trial

A controlled trial (n=20-60, 18-24 month treatment) under a Principal Investigator, with biostatistical supervision and structured safety governance. Designed to include participants beyond the honeymoon window, with minimal residual C-peptide.

Primary Endpoint

Stimulated C-peptide (MMTT), measured longitudinally.

Secondary Measures

  • Insulin requirement trends
  • CGM-derived stability metrics
  • Longitudinal microbiome profiling
  • Inflammatory and immune biomarkers
  • Hormonal signaling markers within the islet axis

Design Architecture

Biomarker-gated progression – phase transitions are triggered by measurable biological shifts rather than fixed timelines.

Conventional care maintained – all participants continue standard insulin therapy under endocrinology supervision.

Independent oversight – Principal Investigator (Endocrinology), biostatistical supervision, and structured safety governance.

The goal is not short-term modulation. The goal is to test whether restoration is biologically measurable.

Two Kinds of Partner – Both Essential

This model cannot exist without collaboration between both approaches. Each brings a strength the model needs, and receives in return something hard to find elsewhere.

Functional & Integrative Physicians
What you bring:
Hands-on experience with a multi-factorial approach, familiarity with advanced testing (microbiome, toxins, functional biomarkers), and the ability to guide families through a complex protocol over time. You are the clinical supervisors of the case-series stage.
What you gain:
A structured, measurement-based research framework for work you are already doing, a protocol grounded in rigorous scientific synthesis, and access to a knowledge community and advanced testing infrastructure.
Endocrinologists & Clinical Researchers
What you bring:
Clinical expertise, academic standing, and experience in trial design and management. You are the Principal Investigator and independent oversight of the trial stage – the layer of rigor and governance that makes the hypothesis seriously testable.
What you gain:
The opportunity to test a bold multi-factorial hypothesis within a controlled framework, publication-grade data, and a position at the frontier of an emerging field connecting microbiome, immunology, and regeneration.

In both cases, we are looking for professionals who are comfortable testing bold but biologically grounded hypotheses, who value disciplined protocol structure, and who understand the distinction between speculation and structured inquiry.

This initiative requires courage – but it also requires rigor.

What This Is Not

  • Not a replacement for standard care – all participants continue their insulin therapy
  • Not a commercialization effort
  • Not a claim of cure
  • Not a bypass of regulatory or ethical oversight

The ambition is high. The discipline must be higher.

Why Engage

If measurable functional recovery is observed in established disease – even partially – the implications would extend across immunology, regeneration science, and long-term metabolic management.

If no signal is observed, the field gains clarity. Either outcome advances understanding.

The Next Step

Whether you are a functional or integrative physician, an endocrinologist, a clinical researcher, or an institutional leader – if you would like to review the full scientific dossier and pilot architecture, we invite you to schedule a conversation with us.

Request a Clinical Discussion